Welcome to our dedicated page for Alps Group SEC filings (Ticker: ALPS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to organize regulatory and related disclosures associated with the ticker symbol ALPS. Public information shows that the symbol has been used in connection with both ALPS Group Inc, a biotechnology research and healthcare platform, and Alpine Summit Energy Partners, Inc., a U.S.-based company that operated and developed oil and gas assets. While no specific SEC filings are listed in the available data for ALPS Group Inc, historical references to Alpine Summit Energy Partners, Inc. mention filings such as Form 8-K and other reports accessible through EDGAR and SEDAR.
For ALPS Group Inc, investors typically look to SEC filings such as annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K for information about its integrated biotechnology platform, its role as parent of Alps Life Sciences Inc, and the details of its business combination with Globalink Investment Inc. These filings would be expected to describe the company’s focus on predictive, preventive, and precision medicine, its corporate structure, and risk factors relevant to its biotechnology and healthcare operations.
For Alpine Summit Energy Partners, Inc., historical filings referenced in news releases include a Form 8-K related to shareholder meeting results and other reports that discuss its operations and financial performance as an oil and gas company. The company also announced a voluntary Chapter 11 process in the U.S. Bankruptcy Court for the Southern District of Texas, which is typically accompanied by court and related disclosure documents.
On a platform that aggregates ALPS filings, users can expect near real-time updates sourced from EDGAR when available, along with tools that provide AI-generated summaries of lengthy documents such as 10-K and 10-Q reports. Such summaries can help clarify segment information, key risk disclosures, and major corporate events. Where insider transaction reports on Form 4 exist for companies associated with the ALPS ticker, they can offer additional insight into equity transactions by directors and officers.
Alps Group Inc is registering up to 6,035,000 ordinary shares issuable upon exercise of outstanding warrants and up to 5,725,546 ordinary shares for resale by existing shareholders. The resale shares represent about 3.44% of the 166,400,326 ordinary shares outstanding as of this prospectus and include founder, PIPE, director and Business Combination consideration shares, some acquired at prices far below the current market price.
The company operates an integrated biotech, medical and wellness platform based in Malaysia. Its pipeline is entirely preclinical, so current revenue comes from aesthetic, healthcare and wellness services used to fund research in areas such as precision and preventive medicine. Warrants are exercisable at $11.50 per share, while the ordinary shares recently closed at $1.00, making exercises unlikely at present.
Key risks include the need for substantial additional funding, a material weakness in internal control over financial reporting, early‑stage clinical and regulatory uncertainty, dependence on third‑party manufacturing, potential selling pressure from registered resale shares, and the challenges of operating as an emerging growth, foreign private issuer based largely in Malaysia.
Alps Group Inc reported that its board appointed Cheing Lye-Ping (Penny) as Chief Financial Officer, effective January 5, 2026. She will lead financial strategy, budgeting, planning and analysis, audit, tax compliance, risk management, accounting, and treasury for the company and its subsidiaries.
Ms. Cheing brings over 30 years of finance and accounting experience, including prior roles as CFO and CEO in Malaysian property and investment businesses, as well as earlier work at Arthur Andersen across multiple industries. Under a one-year executive employment agreement, she will receive an annual base salary of
FAQ
What is the current stock price of Alps Group (ALPS)?
What is the market cap of Alps Group (ALPS)?
